Non-alcoholic fatty liver disease: The mist gradually clears
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is now the commonest liver disorder in the developed world affecting up to a third of individuals. It is closely associated with features of the metabolic syndrome, particularly obesity and diabetes. It can progress to cirrhosis, hepatocellular carcinoma and liver failure and is an increasing indication for transplantation. Dietary and genetic factors determine susceptibility to NAFLD and its progression. NAFLD may also be involved in the pathogenesis of cardiovascular disease. Most patients present with incidentally found abnormal liver blood tests. Diagnosis is usually one of exclusion. Liver biopsy is required for disease staging, but new imaging modalities and biomarkers are emerging which may eventually fulfil this role. There is, as yet no firm evidence-based treatment for NAFLD. Therapy is currently directed at treating components of the metabolic syndrome which may also be beneficial for the liver. The recent elucidation of the mechanisms leading to progressive disease suggests a variety of novel targets worthy of testing in animal models of NAFLD and subsequently in pilot studies in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Self-citationThe Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 3×
“In the most recent study, weight gain and the presence of portal tract fibrosis on index biopsy were the only significant predictors of fibrosis progression [15].”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
The utility of radiological imaging in nonalcoholic fatty liver disease
Saadeh, S., Younossi, Z. M., Remer, E. M., Gramlich, T., Ong, J. P., Hurley, M., Mullen, K. D., Cooper, J. N., & Sheridan, M. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35354 · Cited by 2,110
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005) · Hepatology · doi:10.1002/hep.20734 · Cited by 1,263
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.
Wanless, I. R., & Lentz, J. S. (1990) · Hepatology · doi:10.1002/hep.1840120505 · Cited by 1,191
Serum markers detect the presence of liver fibrosis: A cohort study
Rosenberg, W. M. C., Voelker, M., Thiel, R., Becka, M., Burt, A., Schuppan, D., Hubscher, S., Roskams, T., Pinzani, M., & Arthur, M. J. P. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.052 · Cited by 1,102
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Self-citationMusso, G., Gambino, R., De Michieli, F., Cassader, M., Rizzetto, M., Durazzo, M., Fagà, E., Silli, B., & Pagano, G. (2003) · Hepatology · doi:10.1053/jhep.2003.50132 · Cited by 759
Guha, I. N., Parkes, J., Roderick, P., Chattopadhyay, D., Cross, R., Harris, S., Kaye, P., Burt, A. D., Ryder, S. D., Aithal, G. P., et al. (2008) · Hepatology · doi:10.1002/hep.21984 · Cited by 745
Self-citationVitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
Harrison, S. A., Torgerson, S., Hayashi, P. H., Ward, J. A., & Schenker, S. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.08.005 · Cited by 731
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727 · cited 2×
“To date, all studies have shown improvements in metabolic parameters and steatosis with some, but not all, reporting improvements in necroinflammation and fibrosis [65].”
BackgroundResultBugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691
Wieckowska, A., Zein, N. N., Yerian, L. M., Lopez, R. A., McCullough, A. J., & Feldstein, A. E. (2006) · Hepatology · doi:10.1002/hep.21223 · Cited by 670
Excess weight risk factor for alcoholic liver disease
Naveau, S., Giraud, V., Borotto, E., Aubert, A., Capron, F., & Chaput, J. (1997) · Hepatology · doi:10.1002/hep.510250120 · Cited by 666 · cited 2×
“With respect to alcohol intake, while there is no doubt that obesity increases risk of cirrhosis in heavy drinkers [25] emerging evidence suggests that ‘‘sensible” light alcohol intake may be protective versus NAFLD/ NASH [26,27], an effect that appears likely to be due to the beneficial effect of light alcohol intake…”
BackgroundTherapeutic effects of restricted diet and exercise in obese patients with fatty liver
Ueno, T., Sugawara, H., Sujaku, K., Hashimoto, O., Tsuji, R., Tamaki, S., Torimura, T., Inuzuka, S., Sata, M., & Tanikawa, K. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80287-5 · Cited by 609
Hepatic histology in obese patients undergoing bariatric surgery
Machado, M., Marques-Vidal, P., & Cortez-Pinto, H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.06.013 · Cited by 583
The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease
McCullough, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.004 · Cited by 580
Laurin, J., Lindor, K. D., Crippin, J. S., Gossard, A., Gores, G. J., Ludwig, J., Rakela, J., & McGill, D. B. (1996) · Hepatology · doi:10.1002/hep.510230624 · Cited by 566
Non-alcoholic fatty liver disease and increased risk of cardiovascular disease
Targher, G., & Arcaro, G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.021 · Cited by 551
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Blendis, L., Halpern, Z., & Oren, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.06.020 · Cited by 551
Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
Lavine, J. E. (2000) · The Journal of Pediatrics · doi:10.1016/s0022-3476(00)05040-x · Cited by 531
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 528
Sanyal, A. J., Banas, C., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Heuman, D., Coterrell, A., Fisher, R. A., et al. (2006) · Hepatology · doi:10.1002/hep.21103 · Cited by 522
Yokohama, S., Yoneda, M., Haneda, M., Okamoto, S., Okada, M., Aso, K., Hasegawa, T., Tokusashi, Y., Miyokawa, N., & Nakamura, K. (2004) · Hepatology · doi:10.1002/hep.20420 · Cited by 458
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440 · cited 1×
“Moreover, their potential as a therapy for NAFLD is further increased by evidence from animal models that they may also exert direct anti-fibrotic effects in the liver [70].”
BackgroundBugianesi, E., Manzini, P., D'Antico, S., Vanni, E., Longo, F., Leone, N., Massarenti, P., Piga, A., Marchesini, G., & Rizzetto, M. (2004) · Hepatology · doi:10.1002/hep.20023 · Cited by 440
Abdelmalek, M. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02691-0 · Cited by 439
Tominaga, K., Kurata, J. H., Chen, Y. K., Fujimoto, E., Miyagawa, S., Abe, I., & Kusano, Y. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02208670 · Cited by 406
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Zoppini, G., Zenari, L., Cigolini, M., Falezza, G., & Arcaro, G. (2006) · Diabetes Care · doi:10.2337/dc06-0135 · Cited by 401
Contos, M. J., Cales, W., Sterling, R. K., Luketic, V. A., Shiffman, M. L., Mills, S. A., Fisher, R. A., Ham, J., & Sanyal, A. J. (2001) · Liver Transplantation · doi:10.1053/jlts.2001.23011 · Cited by 400
Day, C. P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.017 · Cited by 395
Self-citationTargher, G., Bertolini, L., Rodella, S., Zoppini, G., Lippi, G., Day, C., & Muggeo, M. (2008) · Diabetologia · doi:10.1007/s00125-007-0897-4 · Cited by 383
Self-citationIp, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
Dietary fat content modifies liver fat in overweight nondiabetic subjects
Westerbacka, J., Lammi, K., Häkkinen, A.-M., Rissanen, A., Salminen, I., Aro, A., & Yki-Järvinen, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1983 · Cited by 379 · cited 1×
“Dietary fat intake has also been shown to correlate with liver fat content and insulin resistance in short-term studies of obese, non-diabetic women – independently of changes in total-body, subcutaneous or abdominal fat [58].”
BackgroundSaviano, M. C., Brunetti, F., Rubino, A., Franzese, A., Vajro, P., Argenziano, A., Puzziello, A., & Iannucci, M. P. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018850223495 · Cited by 365
Dufour, J., Oneta, C. M., Gonvers, J., Bihl, F., Cerny, A., Cereda, J., Zala, J., Helbling, B., Steuerwald, M., & Zimmermann, A. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.025 · Cited by 358
Prevalence of fatty liver in a general population of Okinawa, Japan.
NOMURA, H., KASHIWAGI, S., HAYASHI, J., KAJIYAMA, W., TANI, S., & GOTO, M. (1988) · Japanese Journal of Medicine · doi:10.2169/internalmedicine1962.27.142 · Cited by 355
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
Nair, S., Mason, A., Eason, J., Loss, G., & Perrillo, R. P. (2002) · Hepatology · doi:10.1053/jhep.2002.33713 · Cited by 348
Skelly, M. M., James, P. D., & Ryder, S. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00094-0 · Cited by 310
Gary-Bobo, M., Elachouri, G., Gallas, J. F., Janiak, P., Marini, P., Ravinet-Trillou, C., Chabbert, M., Cruccioli, N., Pfersdorff, C., Roque, C., et al. (2007) · Hepatology · doi:10.1002/hep.21641 · Cited by 304
Klein, S., Mittendorfer, B., Eagon, J. C., Patterson, B., Grant, L., Feirt, N., Seki, E., Brenner, D., Korenblat, K., & McCrea, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.042 · Cited by 289
Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD)
Yoneda, M., Fujita, K., Inamori, M., Nakajima, A., Tamano, M., & Hiraishi, H. (2007) · Gut · doi:10.1136/gut.2007.126417 · Cited by 278
Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease
Ong, J., Younossi, Z. M., Reddy, V., Price, L. L., Gramlich, T., Mayes, J., & Boparai, N. (2001) · Liver Transplantation · doi:10.1053/jlts.2001.24644 · Cited by 258
Obese children with steatohepatitis can develop cirrhosis in childhood
P. Molleston, J. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04360-5 · Cited by 249
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
Lutchman, G., Modi, A., Kleiner, D. E., Promrat, K., Heller, T., Ghany, M., Borg, B., Loomba, R., Liang, T. J., Premkumar, A., et al. (2007) · Hepatology · doi:10.1002/hep.21661 · Cited by 244
&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200111000-00029 · Cited by 243
Benefits of lifestyle modification in NAFLD
Harrison, S. A., & Day, C. P. (2007) · Gut · doi:10.1136/gut.2006.112094 · Cited by 240
Self-citationChronic liver injury during obstructive sleep apnea†
Tanné, F., Gagnadoux, F., Chazouillères, O., Fleury, B., Wendum, D., Lasnier, E., Lebeau, B., Poupon, R., & Serfaty, L. (2005) · Hepatology · doi:10.1002/hep.20725 · Cited by 238
A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis
Adams, L. A., Zein, C. O., Angulo, P., & Lindor, K. D. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40064.x · Cited by 234
Facchini, F. S., Hua, N. W., & Stoohs, R. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.32403 · Cited by 233
Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis
Hirose, A., Ono, M., Saibara, T., Nozaki, Y., Masuda, K., Yoshioka, A., Takahashi, M., Akisawa, N., Iwasaki, S., Oben, J. A., et al. (2007) · Hepatology · doi:10.1002/hep.21638 · Cited by 232
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Paschou, S. A., Polyzos, S. A., Anagnostis, P., Goulis, D. G., Kanaka-Gantenbein, C., Lambrinoudaki, I., Georgopoulos, N. A., & Vryonidou, A. (2020) · Endocrine · doi:10.1007/s12020-019-02085-7 · Cited by 231
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P. (2005) · Hepatology · doi:10.1002/hep.20672 · Cited by 228 · cited 1×
“Features of PCOS (hyperandrogenism) should be sought in young women with suspected NAFLD [35] and clinical evidence of lipodystrophy should be sought in young, non-obese patients in view of its association with NAFLD [42].”
BackgroundIncidence and natural course of fatty liver in the general population: The Dionysos study
Bedogni, G., Miglioli, L., Masutti, F., Castiglione, A., Crocè, L. S., Tiribelli, C., & Bellentani, S. (2007) · Hepatology · doi:10.1002/hep.21827 · Cited by 226
Setji, T. L., Holland, N. D., Sanders, L. L., Pereira, K. C., Diehl, A. M., & Brown, A. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2774 · Cited by 210
Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease
Fracanzani, A. L., Burdick, L., Raselli, S., Pedotti, P., Grigore, L., Santorelli, G., Valenti, L., Maraschi, A., Catapano, A., & Fargion, S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.08.041 · Cited by 209
Adams, L. A., Lindor, K. D., & Angulo, P. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30444.x · Cited by 207
A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients
Harrison, S. A., Fincke, C., Helinski, D., Torgerson, S., & Hayashi, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02153.x · Cited by 191
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Cerda, C., Pérez-Ayuso, R. M., Riquelme, A., Soza, A., Villaseca, P., Sir-Petermann, T., Espinoza, M., Pizarro, M., Solis, N., Miquel, J. F., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.012 · Cited by 187
Genetics of Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease
Wilfred de Alwis, N., & Day, C. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960170 · Cited by 181
Self-citationPrevalence and etiology of altered liver tests: A population‐based survey in a Mediterranean town†
Pendino, G. M., Mariano, A., Surace, P., Caserta, C. A., Fiorillo, M. T., Amante, A., Bruno, S., Mangano, C., Polito, I., Amato, F., et al. (2005) · Hepatology · doi:10.1002/hep.20689 · Cited by 177
Natural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis
Day, C. P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.041 · Cited by 176
Self-citationTargher, G., Bertolini, L., Scala, L., Zoppini, G., Zenari, L., & Falezza, G. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01646.x · Cited by 175
Adachi, M., Osawa, Y., Uchinami, H., Kitamura, T., Accili, D., & Brenner, D. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.033 · Cited by 165
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study
Browning, J. D. (2006) · Hepatology · doi:10.1002/hep.21248 · Cited by 162
Satapathy, S. K., Sakhuja, P., Malhotra, V., Sharma, B. C., & Sarin, S. K. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04756.x · Cited by 160
Fatty liver in familial hypobetalipoproteinemia
Tanoli, T., Yue, P., Yablonskiy, D., & Schonfeld, G. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300508-jlr200 · Cited by 153
Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141 · cited 1×
“It is of interest, therefore, that a recent pilot study in patients with T2DM has shown that long-term high dose insulin therapy results in a reduction of transaminases and hepatic steatosis presumably reflecting the beneficial effects of insulin on blood glucose and adipose tissue lipolysis [68].”
BackgroundMerat, S., Malekzadeh, R., Sohrabi, M., Sotoudeh, M., Rakhshani, N., Sohrabpour, A. A., & Nasseri‐Moghaddam, S. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00441-5 · Cited by 135
Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease
Guha, I. N., Parkes, J., Roderick, P. R., Harris, S., & Rosenberg, W. M. (2006) · Gut · doi:10.1136/gut.2006.091454 · Cited by 127
Cheung, O., Kapoor, A., Puri, P., Sistrun, S., Luketic, V. A., Sargeant, C. C., Contos, M. J., Shiffman, M. L., Stravitz, R. T., Sterling, R. K., et al. (2007) · Hepatology · doi:10.1002/hep.21803 · Cited by 125
Abnormal aminotransferase activity in women with polycystic ovary syndrome
Schwimmer, J. B., Khorram, O., Chiu, V. Y., & Schwimmer, W. B. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.08.020 · Cited by 113
Hussein, O., Grosovski, M., Schlesinger, S., Szvalb, S., & Assy, N. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9631-1 · Cited by 78
Obesity‐related cardiovascular disease: implications of obstructive sleep apnea
Wolk, R., & Somers, V. K. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00508.x · Cited by 77
Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia
Suzuki, A., Angulo, P., St. Sauver, J., Muto, A., Okada, T., & Lindor, K. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01274.x · Cited by 71
Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons
Trombini, P., & Piperno, A. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.004 · Cited by 70
Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice
Oben, J. A., Roskams, T., Yang, S., Lin, H., Sinelli, N., Li, Z., Torbenson, M. S., THOMAS, S. A., & Diehl, A. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01360-3 · Cited by 70
Genes and nonalcoholic fatty liver disease
de Alwis, N. M. W., & Day, C. P. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0027-9 · Cited by 66
Self-citationIchikawa, Y. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.7173 · Cited by 59
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Loria, P., Carulli, N., & Lonardo, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41837_3.x · Cited by 21
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Cited by
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Self-citationProgression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citationBoursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
“The evolution of NAFLD to cirrhosis is not mandatory: Around 20%-30% of NAFLD patients develop NASH, with only some of them further evolving to fibrosis and then cirrhosis.((1,2)) NAFLD is a complex disease driven by the interaction between host genetic background and environmental factors.”
BackgroundPathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Metadata
- Authors
- de Alwis, N. M. W., & Day, C. P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008
- Volume
- 48
- Pages
- S104-S112
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1969149505
- Cited by
- 603
- References
- 93
- FWCI
- 26.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.